Nestlé Replaces Failed Ulcerative Colitis Program
This article was originally published in Scrip
Nestlé's pharmaceutical arm, Nestlé Health Science, has licensed an ulcerative colitis treatment candidate from Lipid Therapeutics. It plans to start a Phase III trial with it in the US in 2016.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.